Pathogenesis and management of intradialytic hypertension
dc.creator | Dousdampanis, P. | en |
dc.creator | Trigka, K. | en |
dc.creator | Giannopoulos, A. | en |
dc.creator | Fourtounas, C. | en |
dc.date.accessioned | 2015-11-23T10:25:54Z | |
dc.date.available | 2015-11-23T10:25:54Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 15734021 | |
dc.identifier.uri | http://hdl.handle.net/11615/27207 | |
dc.description.abstract | Hypertension is common in chronic kidney disease patients especially in those undergoing hemodialysis (HD). Usually, blood pressure falls after the HD session but in some patients a paradoxical increase has been observed during or immediately after HD. This phenomenon is referred as intradialytic hypertension. HD patients with intradialytic hypertension or increased blood pressure during HD present higher cardiovascular (CV) morbidity and mortality rates. The underlying mechanism of intradialytic hypertension is multifactorial. Activation both of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system, volume and sodium overload with concomitant increase in cardiac output, and endothelial dysfunction have been implicated in the pathogenesis of intradialytic hypertension. Given the lack of clinical trials regarding the pathophysiology and management of intradialytic hypertension, current treatment strategies are based mainly on experts’ opinion. The purpose of this review is to describe the pathophysiology of intradialytic hypertension and discuss current strategies in order to improve intradialytic blood pressure management and concomitant HD patients’ outcomes. © 2014 Bentham Science Publishers. | en |
dc.source | Current Hypertension Reviews | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-84922256424&partnerID=40&md5=e51d4dfa19620d419a78dd8c3a2e90ab | |
dc.subject | Hemodialysis | en |
dc.subject | Intradialytic hypertension | en |
dc.subject | Mortality | en |
dc.subject | Overhydration | en |
dc.subject | Pathogenesis | en |
dc.subject | Sodium overload | en |
dc.subject | antihypertensive agent | en |
dc.subject | sodium | en |
dc.subject | adrenergic system | en |
dc.subject | antihypertensive therapy | en |
dc.subject | arterial stiffness | en |
dc.subject | Article | en |
dc.subject | blood pressure measurement | en |
dc.subject | cardiovascular mortality | en |
dc.subject | disease association | en |
dc.subject | endothelial dysfunction | en |
dc.subject | extracellular space | en |
dc.subject | human | en |
dc.subject | hypertension | en |
dc.subject | outcome assessment | en |
dc.subject | priority journal | en |
dc.subject | pulse pressure | en |
dc.subject | sodium balance | en |
dc.subject | sodium blood level | en |
dc.subject | sodium restriction | en |
dc.subject | survival | en |
dc.subject | systemic vascular resistance | en |
dc.subject | vascular resistance | en |
dc.subject | adverse effects | en |
dc.subject | animal | en |
dc.subject | autonomic denervation | en |
dc.subject | blood pressure | en |
dc.subject | complication | en |
dc.subject | electrolyte balance | en |
dc.subject | fluid therapy | en |
dc.subject | innervation | en |
dc.subject | kidney | en |
dc.subject | Kidney Diseases | en |
dc.subject | metabolism | en |
dc.subject | pathophysiology | en |
dc.subject | renal replacement therapy | en |
dc.subject | risk factor | en |
dc.subject | treatment outcome | en |
dc.subject | Animals | en |
dc.subject | Antihypertensive Agents | en |
dc.subject | Humans | en |
dc.subject | Renal Dialysis | en |
dc.subject | Risk Factors | en |
dc.subject | Water-Electrolyte Balance | en |
dc.title | Pathogenesis and management of intradialytic hypertension | en |
dc.type | journalArticle | en |
Αρχεία σε αυτό το τεκμήριο
Αρχεία | Μέγεθος | Τύπος | Προβολή |
---|---|---|---|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |